ArticlePharmaceutics2021
Impact of Laser Speed and Drug Particle Size on Selective Laser Sintering 3D Printing of Amorphous Solid Dispersions.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 48 citations in OpenAlex.
- Polymeric Powders for Powder Bed Fusion: From Chemistry and Powder Characteristics to Process Parameters, Defects and Applications.Polymers · 2026Review
- Laser-Based QR Code Marking on Double Film-Coated Tablets: Balancing Marking Efficiency and Tablet Integrity-A Step Toward Safer Medicines.Pharmaceutics · 2026Article
- Design of SLS 3D-printed pediatric combination printlets of lamivudine and tenofovir disoproxil fumarate by understanding the impact of formulation and process variables on flow, spectral, thermal and performance characteristics.International journal of pharmaceutics · 2025Article
- Printabily of Pharmaceutical-Grade Polymers using Selective Laser Sintering with a COAAPS PharmSciTech · 2025Article
- Revealing Three-Dimensional Printing Technology Advances for Oral Drug Delivery: Application to Central-Nervous-System-Related Diseases.Pharmaceutics · 2025Review
- Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Geometry impact on fundamental properties of theophylline-containing SLS printed pharmaceutical tablets.Frontiers in drug delivery · 2024Article
- Potential Applications and Additive Manufacturing Technology-Based Considerations of Mesoporous Silica: A Review.AAPS PharmSciTech · 2023Review
- Releasing fast and slow: Non-destructive prediction of density and drug release from SLS 3D printed tablets using NIR spectroscopy.International journal of pharmaceutics: X · 2023Article
- Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization.Pharmaceutics · 2022Review
- Laser Sintering Approaches for Bone Tissue Engineering.Polymers · 2022Review
- Prediction of Solid-State Form of SLS 3D Printed Medicines Using NIR and Raman Spectroscopy.Pharmaceutics · 2022Article
- 3D printing of pharmaceuticals for disease treatment.Frontiers in medical technology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research demonstrates the influence of laser speed and the drug particle size on the manufacturing of amorphous solid dispersions (ASD) and dosage forms thereof using selective laser sintering 3-dimensional (3D) printing. One-step manufacturing of ASD is possible using selective laser sintering 3D printing processes, however, the mechanism of ASD formation by this process is not completely understood and it requires further investigation. We hypothesize that the mechanism of ASD formation is the diffusion and dissolution of the drug in the polymeric carrier during the selective laser sintering (SLS) process and the drug particle size plays a critical role in the formation of said ASDs as there is no mixing involved in the sintering process. Herein, indomethacin was used as a model drug and introduced into the feedstock (Kollidon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.